CD8A and neoplasm: In contrast, the anti-tumor effect of this combination disappeared with the addition of an inhibitor of CD8a or in T-cell immune-deficient Rag-/- mice, suggesting that SFRT enhances the efficacy of immune checkpoint inhibitors via CD8+ T lymphocytes (95).